Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Fitzgerald

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Blood|July 19, 2014
Targeted diphtheria toxin to treat BPDCNDavid J FitzGerald
Analytical Biochemistry|May 2, 2006
A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxinDiana V Pastrana, David J FitzGerald
International Journal of Cancer|July 24, 2012
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell linesAbid R Mattoo, David J FitzGerald
Molecular Cancer Therapeutics|April 18, 2014
ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxinAntonella Antignani, Robert Sarnovsky, David J FitzGerald
Cancer Research|January 26, 2013
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxinXiu Fen Liu, David J FitzGerald, Ira Pastan
Frontiers in Immunology|November 7, 2022
Managing the TME to improve the efficacy of cancer therapyMaria Teresa Bilotta, Antonella Antignani, David J Fitzgerald
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cellsKevin Hollevoet, Antonella Antignani, David J Fitzgerald, et al.
Cancer Research|August 5, 2008
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activityXing Du, Richard Beers, David J Fitzgerald, et al.
Annual Review of Medicine|October 25, 2006
Immunotoxin treatment of cancerIra Pastan, Raffit Hassan, David J FitzGerald, et al.
Molecular Cancer Therapeutics|October 23, 2013
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitorsXiu-Fen Liu, Laiman Xiang, David J FitzGerald, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Blood|July 19, 2014
Targeted diphtheria toxin to treat BPDCNDavid J FitzGerald
Analytical Biochemistry|May 2, 2006
A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxinDiana V Pastrana, David J FitzGerald
International Journal of Cancer|July 24, 2012
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell linesAbid R Mattoo, David J FitzGerald
Molecular Cancer Therapeutics|April 18, 2014
ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxinAntonella Antignani, Robert Sarnovsky, David J FitzGerald
Cancer Research|January 26, 2013
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxinXiu Fen Liu, David J FitzGerald, Ira Pastan
Frontiers in Immunology|November 7, 2022
Managing the TME to improve the efficacy of cancer therapyMaria Teresa Bilotta, Antonella Antignani, David J Fitzgerald
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cellsKevin Hollevoet, Antonella Antignani, David J Fitzgerald, et al.
Cancer Research|August 5, 2008
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activityXing Du, Richard Beers, David J Fitzgerald, et al.
Annual Review of Medicine|October 25, 2006
Immunotoxin treatment of cancerIra Pastan, Raffit Hassan, David J FitzGerald, et al.
Molecular Cancer Therapeutics|October 23, 2013
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitorsXiu-Fen Liu, Laiman Xiang, David J FitzGerald, et al.
Pageof 5